SELECT-LIFE

Completed

SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial

SELECT-LIFE (SELECT Follow-up Study to Evaluate Long-term Impact oF Anti-obEsity Medication)

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

3,439

actual

Study population

Cardiovascular disease, Obesity / overweight

Key I/E criterion

—

Primary endpoints

•All-cause death•Expanded / custom MACE composite (All-cause death, Non-fatal MI, Non-fatal stroke)•Non-fatal MI

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04972721

Org study IDEX9536-4750

Secondary IDU1111-1255-5644World Health Organization (WHO)

Timeline

Milestones

Study first posted2021-07-22actual

Study start2023-09-01actual

Primary completion2025-08-25actual

Study completion2025-08-25actual

Last update posted2026-02-11actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Cardiovascular diseaseObesity / overweight

Eligibility

Who can enroll

Minimum age45 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Participants of the SELECT trial (EX9536-4388 ) are invited to transition to SELECT-LIFE (follow-up study) when SELECT ends.

Inclusion criteria

•Randomized into the SELECT clinical trial (EX9536-4388) and has not withdrawn consent, regardless of level of participation, dose achieved or treatment discontinuation.

•Signed SELECT-LIFE consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

Exclusion criteria

•Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Endpoints (16)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiovascular outcomes

Other clinical outcomes

Weight & body composition

Glycemic / diabetes

Patient-reported / QoL

Cardiovascular outcomes

7 endpoints

Primary/protocol endpoint

Time to all-cause death

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

All-cause death

time to event, event

SNOMED 419620001

Primary/protocol endpoint

Time to first occurrence of a composite consisting of: All-cause death, non-fatal myocardial infarction and non-fatal stroke

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

Expanded / custom MACE composite

time to event, event

componentsAll-cause death, Non-fatal MI, Non-fatal stroke

Primary/protocol endpoint

Time to first occurrence of non-fatal myocardial infarction

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

Non-fatal MI

time to event, event

SNOMED 22298006

Primary/protocol endpoint

Time to first occurrence of non-fatal stroke

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

Non-fatal stroke

time to event, event

SNOMED 230690007

Primary/protocol endpoint

Total number of myocardial infarctions

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

Myocardial infarction (any)

event count, event

SNOMED 22298006

Primary/protocol endpoint

Total number of strokes

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

Stroke (any)

event count, event

SNOMED 230690007

Primary/protocol endpoint

Total Days of hospitalisation from P-FU (is the end of trial visit in SELECT) to biannual assessments, (year 1-10)

Time frame:From P-FU(is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to120 months)

event count, event

Weight & body composition

1 endpoint

Primary/protocol endpoint

Change in body weight from V-EOT (is the end of treatment visit in SELECT) to biannual assessments, (year 1-10)

Time frame:From V-EOT (is the end of treatment visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to120 months)

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

Time to diagnosis of type 2 diabetes

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

Time to T2DM onset

time to event, event

Patient-reported / QoL

1 endpoint

Primary/protocol endpoint

Change in Patient reported quality of life questionnaire (EQ-5D-5L) from V-EOT (is the end of treatment visit in SELECT) to biannual assessments, (year 1-10)

Time frame:From V-EOT (is the end of treatment visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to120 months)

EQ-5D index

change from baseline, improvement

Other clinical outcomes

6 endpoints

Primary/protocol endpoint

Time to first occurrence of any type of cancer

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

time to event, event

Primary/protocol endpoint

Time to first occurrence of a composite of obesity related cancer defined by WHO

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

time to event, event

Primary/protocol endpoint

Time to first occurrence of knee replacement

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

time to event, event

Primary/protocol endpoint

Time to first occurrence of bariatric surgery

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

time to event, event

Primary/protocol endpoint

Time to first occurrence of anti-obesity medical treatment

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

time to event, event

Primary/protocol endpoint

Time to first occurrence of use of continuous positive airways pressure (CPAP) device

Time frame:From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months)

time to event, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.